Clinical trials: Rituximab, completed
Chronic Lymphocytic Leukemia
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00769522
- Testing
- Rituximab, Bendamustine, Cyclophosphamide
- Where
- Germany
- Volunteers
- 564 people
- Sponsor
- German CLL Study Group
CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
This phase II trial studies the side effects and best dose of bortezomib when given with chemotherapy and to see how well they work in treating participants with lymphoid malignancies undergoing stem cell transplant.
- Conditions
- CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
- Trial name
- NCT00439556
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Invasive Pneumococcal Infection
Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy
The study hypothesis is that a "reinforced" pneumococcal combined vaccine strategy in patients with ANCA-associated vasculitides treated with rituximab will induce a better immune response than the current standard regimen, with…
- Trial name
- PNEUMOVAS (NCT03069703)
- Testing
- PCV13, PPV23, Rituximab
- Where
- France
- Volunteers
- 96 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsing-remitting Multiple Sclerosis
COMparison Between All immunoTherapies for Multiple Sclerosis.
The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based…
- Trial name
- COMBAT-MS (NCT03193866)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 3,526 people
- Sponsor
- Karolinska Institutet
Multiple Myeloma and Plasma Cell Neoplasm
Rituximab in Treating Patients With Multiple Myeloma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab in treating…
- Trial name
- NCT00003554
- Testing
- rituximab, melphalan, prednisone
- Where
- United States
- Sponsor
- The Cleveland Clinic
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well they work in treating patients with relapsed or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00601718
- Testing
- vorinostat, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Lymphoma
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
After conventional induction treatment with R-CHOP (Rituximab, cyclophosphamide, adriamycin, vincristine and prednisone) the patients are randomized to: A: Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4…
- Trial name
- NCT00662948
- Testing
- Rituximab, Ibritumomab tiuxetan
- Where
- 21 sites in Spain
- Volunteers
- 149 people
- Sponsor
- PETHEMA Foundation
Autoimmune Adrenocortical Failure
Rescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS)
This is a pilot study of B lymphocyte depletion therapy in an attempt to salvage adrenal steroidogenic capacity in ten subjects with early autoimmune Addison's disease.
- Trial name
- RADS (NCT00753597)
- Testing
- Solu-medrone, Mabthera
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Newcastle University
Leukemia Lymphocytic Chronic B-Cell
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD).
- Trial name
- NCT01744626
- Testing
- CC-292, Rituximab
- Where
- 8 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
This phase II trial studies how well giving vorinostat, cladribine, and rituximab together works in treating patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or B cell non-Hodgkin's lymphoma (NHL)…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT00764517
- Testing
- Cladribine, Laboratory Biomarker Analysis, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- OHSU Knight Cancer Institute
Lymphoma
Non-Myeloablative Allogeneic Stem Cell Transplantation
1. To determine the safety and efficacy of non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for patients with advanced or recurrent mantle cell…
- Trial name
- NCT00525876
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Autoimmune Diseases
Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab
Rituximab is a very effective drug used to treat many inflammatory diseases. These diseases include, for example, rheumatoid arthritis, multiple sclerosis and systemic autoimmune diseases.
- Trial name
- EXPRIME (NCT03778840)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Lille
Antibody-mediated Rejection, Kidney Transplant Rejection
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney transplant recipients (KTRs). Although it is a well characterized entity, there is limited data regarding effective treatment options for…
- Conditions
- Antibody-mediated Rejection, Kidney Transplant Rejection, Graft Loss
- Trial name
- NCT04367610
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Istanbul University
Immune Thrombocytopenia
Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia
Previous studies have shown that increase level of BAFF could promote the settlement of long-lived plasma cells in the spleen of ITP patients treated with anti-CD20.
- Trial name
- RITUX PLUS (NCT03154385)
- Testing
- Rituximab (Mabthera ®) Belimumab (Benlysta ®)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Myeloproliferative Disorders, Leukemia
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00691015
- Testing
- rituximab, busulfan, carmustine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-Hodgkin's Lymphoma
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this…
- Trial name
- BVR (NCT00547534)
- Testing
- bortezomib, bendamustine, rituximab
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Rochester
Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT02461316
- Testing
- No intervention
- Where
- 3 sites in Serbia
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
This is a single-arm, open-label, multicenter study of Iodine I-131 Anti B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for treatment of non-Hodgkin's lymphoma (NHL) who were previously treated with rituximab antibody.
- Trial name
- NCT00996593
- Testing
- Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
- Volunteers
- 43 people
- Sponsor
- GlaxoSmithKline
Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP)
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
The purpose of the study is to evaluate the safety and efficacy of rituximab in children ages 18 months to 18 years, who have severe, chronic ITP.
- Trial name
- NCT01713738
- Testing
- rituximab
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Neufeld, Ellis J, MD, PhD
Non-Hodgkins Lymphoma
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell…
- Trial name
- NCT00193505
- Testing
- Ifosfamide, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.